Vaccine delay: Moderna's flu/COVID combination vaccine hit by deprioritization, FDA delay

Moderna's flu/COVID combination vaccine hit by deprioritization, FDA delay Moderna is deprioritizing< | Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news of a delay to the expected approval of the vaccine in older adults. Nick Paul Taylor Fierce Biotech

...

The biotech has deprioritized the development of mRNA-1083 in people aged 18 to 49 years. Moderna is still working to get the vaccine to older adults, but the process is taking longer than hoped. Having filed for approval using immunogenicity data, Moderna has learned the FDA wants to see phase 3 efficacy data before signing off on the vaccine. The request pushes the targeted approval date back into 2026.

...